Opca Bolnica Zadar — Clinical Trial Site

19 Registered trials

6 Currently recruiting

Organisation

Opca Bolnica Zadar

Location

Zadar, Croatia

Identifier

ORG-100030816

Address

Ulica Boze Pericica 5, 23000, Croatia

Departments

Cardiology
Department for hematology
Department for internal disease
Department for Rheumatology
Department of dermatology
Department of Internal Medicine
Department of Internal Medicine, Gastroenterology
Department of Nephrology
Department of Oncology and nuclear medicine
gastroenterology
Internal Medicine
Odjel za oftalmologiju i optometriju
Oncology and nuclear medicine
Pulmonology

Clinical trials at this site (19)

Search interface

A Phase 3, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib in Subjects with Active Pso… Pending

2025-522586-30-00 Psoriatic Arthritis 5
A study to assess the efficacy and safety of efgartigimod PH20 SC in adults with systemic sclerosis (eSScape) Recruiting

2024-514539-67-00 Systemic Sclerosis 4 2025-06-27
A Study of Zasocitinib in Adults with Psoriatic Arthritis Who Have Not Taken Biologic Medicines Recruiting

2024-513111-27-00 Psoriatic Arthritis 5 2025-06-26
A Phase 2 Study to Evaluate MORF-057 in Adults with Moderately to Severely Active Crohn’s Disease Recruiting

2023-508158-24-00 Moderately to Severely Active Crohn’s Disease 4 2024-06-25
A study to discover if ZED1227 can improve continued celiac disease symptoms despite a gluten-free diet Recruiting

2023-506150-21-00 Celiac Disease 4 2024-05-29
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 ER+/HER2- Early Breast Cancer 5 2024-03-25
A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab… Recruiting

2023-503224-66-00 Atrial Fibrillation 5 2023-10-31
Hidradenitis Suppurativa: Evaluation of lutikizumab in Adult and Adolescent Subjects Ended

2024-510730-40-00 Hidradenitis Suppurativa 5 2024-12-12
Study to Evaluate Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA 3 Study) Ended

2023-509300-14-00 Severe hypertriglyceridemia (SHTG) 5 2024-10-31
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change i… Ended

2023-506906-38-00 Follicular Lymphoma 5 2024-05-23
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic … Ended

2023-503655-10-00 Systemic Lupus Erythematosus (SLE). 5 2023-11-20
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Atrial Fibrillation 5 2023-08-23
Atacicept in Subjects with IgA Nephropathy (ORIGIN and ORIGIN 3) Ended

2023-503772-24-00 IgA Nephropathy 10 2021-09-15
Efficacy and Safety of Rosnilimab in Subjects with Ulcerative Colitis Ended

2023-508679-34-00 Ulcerative Colitis 4 2024-07-30
A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) Ended

2023-503693-20-01 Severe eosinophilic asthma 5 2024-04-10
Part C of A Phase 1b/2a Study of LY2880070 in Patients with Advanced or Metastatic Cancer Ended

2023-503459-91-00 Advanced or Metastatic Cancer 4 2023-11-21
ABTECT-2 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -2 Ended

2022-500536-11-01 Moderately to severely active ulcerative colitis 5 2023-06-08
The efficacy and safety of two doses of CHF6001 DPI as add-on to maintenance COPD triple therapy Ended

2023-510174-13-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2021-06-17
A Clinical Trial to compare Efficacy, Safety, Tolerability of RBS-001 to Eylea® in Subjects with Neovascular Age-Related Macular Degeneratio… Ended

2023-509206-29-00 Neovascular age-related macular degeneration (nAMD) 5